PMID- 36369625
OWN - NLM
STAT- MEDLINE
DCOM- 20230315
LR  - 20230315
IS  - 2520-8721 (Electronic)
IS  - 1109-3099 (Linking)
VI  - 22
IP  - 1
DP  - 2023 Mar
TI  - Influence of fasting plasma glucose-lowering rate on BNP levels in type 2 
      diabetes mellitus patients with coronary microcirculation dysfunction.
PG  - 33-43
LID - 10.1007/s42000-022-00404-8 [doi]
AB  - AIM: The aim was to analyze the influence of fasting plasma glucose-lowering rate 
      (FPGLR) on plasma BNP levels in type 2 diabetes mellitus (T2DM) patients with 
      coronary microcirculation dysfunction (CMD) and to determine the optimal FPGLR 
      for these patients. METHODS: A total of 170 T2DM patients who received intensive 
      glucose-lowering therapy during hospitalization in the First Affiliated Hospital 
      of Harbin Medical University were enrolled. Ninety-two patients with CMD and 78 
      patients without CMD were assigned to a study and a control group, respectively. 
      The study group was stratified as S1 (4.1 ~ 6.0 mmol.L(-1).day(-1)), S2 
      (2.1 ~ 4.0 mmol.L(-1).day(-1)), and S3 (</= 2.0 mmol.L(-1).day(-1)) by different 
      FPGLR, and the same in the control group (C1, C2, and C3). The plasma BNP levels 
      with the same FPGLR were compared between the study and the control group, and 
      patients with a different FPGLR in the study group were also compared. RESULTS: 
      In the study and the control group, the BNP level in S1 was significantly higher 
      than that in C1 (87 vs. 12 pg/ml, P < 0.001), although there was no significant 
      difference between S2 and C2, S3 and C3. In the study group, the BNP level in S1 
      was significantly higher than that in S2 (87 vs. 22 pg/ml, P < 0.001) and S3 (87 
      vs. 15 pg/ml, P < 0.001), but there was no significant difference between S2 and 
      S3. CONCLUSION: Rapid intensive glucose-lowering may lead to increased plasma BNP 
      levels in T2DM patients with CMD. Optimal FPGLR for these patients was determined 
      to be no more than 4.0 mmol.L(-1).day(-1).
CI  - (c) 2022. The Author(s), under exclusive licence to Hellenic Endocrine Society.
FAU - Zhang, Ziying
AU  - Zhang Z
AD  - Department of Endocrinology, The Third Affiliated Hospital of Shenzhen 
      University, Shenzhen, 518000, People's Republic of China.
FAU - Chen, Yangwen
AU  - Chen Y
AD  - The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, 
      People's Republic of China.
FAU - Wang, Qian
AU  - Wang Q
AD  - The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, 
      People's Republic of China.
FAU - Xie, Lingli
AU  - Xie L
AD  - Department of Endocrinology, The Third Affiliated Hospital of Shenzhen 
      University, Shenzhen, 518000, People's Republic of China.
FAU - Shan, Yongyan
AU  - Shan Y
AD  - The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, 
      People's Republic of China.
FAU - Yang, Ning
AU  - Yang N
AD  - The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, 
      People's Republic of China. huakaixx2020@126.com.
FAU - Wu, Weihua
AU  - Wu W
AUID- ORCID: 0000-0002-3173-0183
AD  - Department of Endocrinology, The Third Affiliated Hospital of Shenzhen 
      University, Shenzhen, 518000, People's Republic of China. wwhnfmk@163.com.
LA  - eng
PT  - Journal Article
DEP - 20221112
PL  - Switzerland
TA  - Hormones (Athens)
JT  - Hormones (Athens, Greece)
JID - 101142469
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Blood Glucose
MH  - Microcirculation
MH  - Fasting
OTO - NOTNLM
OT  - Brain natriuretic peptide levels
OT  - Coronary microcirculation dysfunction
OT  - Glucose-lowering rate
OT  - Type 2 diabetes mellitus
EDAT- 2022/11/13 06:00
MHDA- 2023/03/16 06:00
CRDT- 2022/11/12 00:49
PHST- 2021/11/30 00:00 [received]
PHST- 2022/10/06 00:00 [accepted]
PHST- 2022/11/13 06:00 [pubmed]
PHST- 2023/03/16 06:00 [medline]
PHST- 2022/11/12 00:49 [entrez]
AID - 10.1007/s42000-022-00404-8 [pii]
AID - 10.1007/s42000-022-00404-8 [doi]
PST - ppublish
SO  - Hormones (Athens). 2023 Mar;22(1):33-43. doi: 10.1007/s42000-022-00404-8. Epub 
      2022 Nov 12.